Home / Blog / 59

DelveInsight Blog

Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.

Search by Categories

Roche’s Columvi Phase III STARGLO Trial; Novartis’ Fabhalta Latest Data; Vertex’s Alpine Immune Sciences Acquisition; Telix Pharmaceuticals’ TLX101-CDx Fast Track Designation; NovelMed’s NM5072 Orphan Drug Designation

Roche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that individuals with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who had previously undergone at least one treatment and were not eligible for autologous stem cell transplant, had longer life expectancy when treated with Columvi® (glofitamab) alongside gemcitabine and oxaliplatin (GemOx) compared to those treated…
pharma-news-for-roche-novartis-vertex-telix

ENHERTU: Another Triumph to Celebrate for AstraZeneca and Daiichi Sankyo

ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous systemic treatment and have exhausted other available treatment options. With this approval, ENHERTU achieves a groundbreaking milestone as the premier therapy targeting HER2 across various tumor types, marking the first ADC to secure such a broad indication. ENHERTU, an ADC targeting HER2, was…
enhertu-for-her2-positive-solid-tumors

Evenamide (NW-3509): Advancing Solutions for Treatment-Resistant Schizophrenia

Evenamide (NW-3509)– derived from Newron's ion channel program, tackles schizophrenia with its unique mechanism, balancing glutamate levels and blocking aberrant sodium channel activity to restore neuronal function without compromising normal excitability. Evenamide, based on a new concept in treating inadequate/non-response in schizophrenia, enhances the effects of antipsychotic medications by synergistically targeting glutamate and dopamine systems, thereby optimizing the therapeutic approach.  Newron Pharmaceuticals’ poster featuring their drug candidate, evenamide (NW-3509), was presented at the Congress of the Schizophrenia International Research Society (SIRS) in Florence, Italy, held from April 3rd to 7th,…
evenamide-phase-ii-iii-trial-result

Trending

rl-007-promise-for-cognitive-enhancement-in-schizophrenia
Beyond Symptom Management: RL-007’s Promise for Cognitive Enhancement i...

In the landscape of schizophrenia treatment, there are significant gaps that affect patients' lives profoundly.…

Find out more
lyn-005-in-schizophrenia-treatment
Breaking Boundaries: The Promise of LYN-005 in Schizophrenia Treatment

LYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders…

Find out more
iclepertin-for-cias-treatment
Iclepertin: Bridging the Gap in CIAS Treatment – the Answer to an Unmet...

Despite the urgent need for novel treatments, drug development for cognitive impairment associated with schizophrenia…

Find out more
brilaroxazine-for-schizophrenia
Hope on the Horizon: Brilaroxazine’s Promise for Schizophrenia Patients

Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine…

Find out more
unmet-needs-in-glaucoma-treatment
The Unmet Needs in Glaucoma Treatment: Bridging Gaps for Better Vision Care

Glaucoma, often dubbed as the “silent thief of sight,” poses a significant challenge in the…

Find out more
doc1021-phase-i-results
DOC1021 – Unveiling Hope: Diakonos Oncology’s Breakthrough in Glioblast...

Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous…

Find out more

Artificial Intelligence (AI) in Mental Health
Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market

FDA granted accelerated approval to Lilly’s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.

Find More
dermatomyositis-treatment

Unraveling the Complexities of Dermatomyositis Treatment: A Comprehensive Review and Future Perspectives

Read More
stelara-biosimilar-wezlana

Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara

Read More
Cryotherapy Market Analysis

Navigating the Booming Cryotherapy Market and Its Future Outlook

Read More
label-expansion-of-xtandi-and-keytruda

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

Read More

voquezna-for-gerd-treatment
Phathom Secures Dual FDA Approvals for Voquezna Following Impurity Setback

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

Find More
recent-developments-in-nsclc-treatment
The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Find More
Rehabilitation Equipment Market Analysis
Evaluating the Growing Role of Rehabilitation Equipment in Revitalizing Lives and Improving the Treatment Outcome

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone ...

Find More

Launch Landscape Analysis
Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

Find More
Product Assessment
Product Assessment

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

Find More
Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Find More
Out Licensing Opportunity
Out-Licensing Opportunity

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

Find More
In Licensing Opportunity
In-Licensing Opportunity

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

Find More
Go To Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

Find More

See How We Do It

Our Consulting Services
Consulting Services

Optimized, competent, and dependable solutions to tackle fast-paced pharma market challenges.

Our Pharma Market Reports
Pharma Market Reports

Credible, data-driven, & analytical pharma & biotech market research & analysis for a holistic understanding.

Our MedTech Insights
MedTech Insights

Clinical solutions for vastly expanding diagnostics, digital therapeutics, & the MedTech industry.